text

Pipeline

content-image

Our oncology pipeline includes multiple dual-payload immunotherapies and targeted vector immunotherapies.

Our lead candidate, GEN2, carries a proprietary pro-drug facilitated cancer killing gene, Herpes Simplex Virus enhanced Thymidine Kinase (HSV-eTK) and an immunocytokine, Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF).  Our HSV-eTK gene has been engineered in-house for increased cancer cell killing.  These therapeutic genes work together to release patient specific neoantigens and induce the immune system to activate a persistent and systemic response against the cancer.

Additional assets are under development for infectious disease applications.

Pipeline

Candidate

Indication

Discovery

Preclinical

IND-
Enabling

IND

Clinical - Phase I

Candidate
GEN2
Indication
Solid Tumors
Discovery
Preclinical
IND-
Enabling
IND
Clinical - Phase I
Candidate
GEN-1013
Indication
Solid Tumors
Discovery
Preclinical
IND-
Enabling
IND
Clinical - Phase I
Candidate
GEN-0X00
Indication
Solid Tumors
Discovery
Preclinical
IND-
Enabling
IND
Clinical - Phase I
Candidate
GEN-1045
GEN-4035
Indication
Influenza/
Undisclosed
Discovery
Preclinical
IND-
Enabling
IND
Clinical - Phase I
"Hover over product to see more detailed description"
Platform carrying proprietary pro-drug facilitated cancer killing gene, Herpes Simplex Virus enhanced Thymidine Kinase (HSV-eTK) and an immunocytokine, Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) as therapeutic genes.
Platform carrying proprietary pro-drug facilitated cancer killing gene, Herpes Simplex Virus enhanced Thymidine Kinase (HSV-eTK) and an immunocytokine, Interleukin 12 (IL-12) as therapeutic genes.
Platform with modified envelope proteins to target specific cancer types (targets undisclosed). Can be engineered with therapeutic genes of interest.
Non-integrating platform carrying gene coding for influenza antigens for vaccine applications.